Tyra Biosciences (TYRA) Income towards Parent Company (2020 - 2026)

Tyra Biosciences has reported Income towards Parent Company for 7 years, with the latest figure at -$39.3 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 39.64% year-over-year to -$39.3 million; the trailing twelve-month figure through Mar 2026 stood at -$131.1 million (down 35.95% YoY), and the FY2025 full-year result was -$119.9 million, down 38.7% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$39.3 million, down from -$33.8 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$11.9 million in Q1 2023, with the low at -$39.3 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$21.8 million across 5 years, with a median of -$21.2 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 252.25% — and 2023, when it rose 19.86%.
• Tyra Biosciences' Income towards Parent Company stood at -$12.9 million in 2022, then plunged by 77.05% to -$22.8 million in 2023, then slipped by 12.01% to -$25.6 million in 2024, then slumped by 32.31% to -$33.8 million in 2025, then retreated by 16.17% to -$39.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$39.3 million (Q1 2026), -$33.8 million (Q4 2025), and -$29.9 million (Q3 2025), per Business Quant data.